Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16762235 | 0.85 | JAK2 (0.35) | MAPK1JAK2BTK | |
| SCHEMBL20661095 | 0.84 | CYP3A4 (0.43) | CD44CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL23974414 | 0.82 | GAA (0.39) | CYP3A4TSHRMAPK1JAK2BTK | |
| SCHEMBL29885660 | 0.82 | GAA (0.39) | CYP3A4TSHRMAPK1JAK2BTK | |
| SCHEMBL14790572 | 0.81 | LPL (0.34) | CD44JAK2BTKGAAALDH1A1 | |
| SCHEMBL30296221 | 0.81 | LPL (0.34) | CD44JAK2BTKGAAALDH1A1 | |
| SCHEMBL30296224 | 0.81 | LPL (0.34) | CD44JAK2BTKGAAALDH1A1 | |
| SCHEMBL30982000 | 0.80 | GAA (0.36) | CD44CYP3A4TSHRMAPK1JAK2 | |
| SCHEMBL3690683 | 0.80 | CYP3A4 (0.43) | CYP3A4TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL27409909 | 0.80 | GAA (0.36) | CD44CYP3A4TSHRMAPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | CD44 1419/4885CYP3A4 4247/4885TSHR 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.